Schrödinger, Inc. (SDGR)
Market Cap | 1.78B |
Revenue (ttm) | 180.96M |
Net Income (ttm) | -149.19M |
Shares Out | 71.49M |
EPS (ttm) | -2.10 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 58,858 |
Open | 24.91 |
Previous Close | 24.63 |
Day's Range | 24.81 - 25.29 |
52-Week Range | 15.85 - 36.33 |
Beta | 1.02 |
Analysts | Buy |
Price Target | 52.40 (+109.81%) |
Earnings Date | May 2, 2023 |
About SDGR
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. T... [Read more]
Financial Performance
In 2022, Schrodinger's revenue was $180.96 million, an increase of 31.19% compared to the previous year's $137.93 million. Losses were -$149.19 million, 48.6% more than in 2021.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for SDGR stock is "Buy." The 12-month stock price forecast is $52.4, which is an increase of 109.81% from the latest price.
News

3 Tech Stocks to Buy for the Fourth Industrial Revolution
The Fourth Industrial Revolution refers to the use of multiple advanced technologies, including “artificial intelligence (AI), robotics, [and] the Internet of Things (IoT).” Also in the mix are “faste...

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on March ...

3 Amazing AI Stocks for Your March Buy List
The Street is realizing what computer scientists and many observers have known for years: artificial intelligence has become tremendously powerful and will have a huge impact on our lives. Moreover, A...

Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117 in January 2021. Schrodinger's artificial int...

Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 22% and 16.74%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Schrödinger Reports Strong Fourth Quarter and Full-Year 2022 Financial Results
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial res...

Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on Februa...

Schrödinger Receives $111.3 Million Distribution from Sale of Nimbus's TYK2 Inhibitor to Takeda
NEW YORK--(BUSINESS WIRE)--Schrödinger Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported the receipt of ...

Schrödinger to Announce Fourth Quarter and Full-Year 2022 Financial Results on February 28
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its fourth quarter and ...

Schrödinger to Present at SVB Securities Global Biopharma Conference
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management w...

Schrödinger Provides Update on Progress Across the Business and Outlines 2023 Company Strategic Priorities
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on...

Why These 7 Healthcare Stocks Could Soar in 2023
With the healthcare sector poised to grow significantly in the coming years, healthcare stocks to buy present a fantastic opportunity for investors. Healthcare is something that everyone will need at ...

7 Drug Stocks That Will Soar in 2023
Choosing the best drug stocks to buy can be dicey because drug stocks have disadvantages and advantages. On the negative side, you often have to wait many years for promising drugs to prove themselves...

Schrödinger Presents New Preclinical Data Supporting Advancement of CDC7 Inhibitor Development Candidate, SGR-2921, at American Society of Hematology 2022 Annual Meeting
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced new preclin...

Schrödinger to Present at Piper Sandler 34th Annual Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management w...

Schrödinger to Present at Jefferies 13th Annual London Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that management will participate in the Jefferies 13th Annual London Healthcare Conference in London, UK.

3 Hypergrowth Stocks That Will Make You a Millionaire by 2027
During the current earnings season, a few of the companies whose stocks I own delivered great third-quarter results. These results, along with their other achievements, shows that the firms' technolog...

Schrodinger, Inc. (SDGR) Reports Q3 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 8.20% and 14.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Schrödinger Reports Third Quarter 2022 Financial Results
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported financial results for the third quarter of 2022 and provided an update on the company.

Schrödinger To Present New Preclinical Data From Its CDC7 Inhibitor Program At American Society Of Hematology 2022 Annual Meeting
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that new prec...

Schrödinger to Announce Third Quarter 2022 Financial Results on November 3
NEW YORK--(BUSINESS WIRE)---- $SDGR--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its third qua...

Schrödinger Hosts Platform Day
NEW YORK--(BUSINESS WIRE)--Schrödinger is providing a detailed review of its technology platform during its Platform Day today, October 6, from 10:00 a.m. - 12:00 p.m. ET.

Schrödinger to Host Platform Day on October 6, 2022
NEW YORK--(BUSINESS WIRE)---- $SDGR--Schrödinger announced that it will host Platform Day on October 6, 2022.

7 Small-Cap Stock Picks to Beat the September Market Slump
When compiling my small-cap stock picks, I tried to choose names that seemed to be benefiting from this new, more “risk-on” environment. Among the encouraging features of the August Consumer Price Ind...

Schrödinger to Present at Citi's 17th Annual BioPharma Conference
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will present at Citi's 17th Annual BioPharma Conference.